Personalized Cancer Therapy 



 Dr. Selvaraj and his colleagues have conducted extensive studies into the preparation, characterization, function, and mechanism of action of GPI-ISM-modified tumor cells and tumor-membrane vesicles.  Their work has demonstrated the effectiveness of the tumor-cells/membranes containing GPI-ISMs in eliminating and/or suppressing the growth of cancer cells in murine models of cancer. Such studies resulted in the following selected publications in peer-reviewed journals:

  • McHugh RS, Ahmed SN, Wang YC, Sell KW, Selvaraj P. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA 1995; 92:8059-63. PubMed PMID: 7544014; PubMed Central PMCID: PMC41286.
  • McHugh RS, Nagarajan S, Wang YC, Sell KW, Selvaraj P. Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Research 1999. 59:2433-7. PubMed PMID: 10344754.
  • Poloso NJ, Nagarajan S, Bumgarner GW, Selvaraj P. Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules. Vaccine 2001. 19:2029-38. PubMed PMID: 11228374.
  • Nagarajan S, Selvaraj P. Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: a potential approach for local delivery of cytokines during vaccination. Vaccine 2006. 24:2264-74. PubMed PMID: 16376465.
  • Bozeman EN, Cimino-Mathews A, Machiah DK, Patel JM, Krishnamoorthy A, Tien L, Shashidharamurthy R, Selvaraj P. Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model. Vaccine 2013. 31:2449-56. PubMed PMID: 23541884; PubMed Central PMCID: PMC3686649.
  • Patel JM, Vartabedian VF, Bozeman EN, Caoyonan BE, Srivatsan S, Pack CD, Dey P, D'Souza MJ, Yang L, Selvaraj P. Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth. Biomaterials 2016. 74:231-244. PMID: 26461116. PMCID: PMC4661141
  • Bozeman EN, He S, Shafizadeh Y, Selvaraj P. Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12.   Human Vaccines & Immunotherapeutics 2016. 12:421-30.